The present Competitive Intelligence Report about PDGF-R agonists and antagonists provides a competitor evaluation in the field of platelet derived growth factor receptor (PDGF-R) or PDGF targeting molecules for wound healing, bone formation or treatment of cancer as of October 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Growth factors are extracellular signaling polypeptides regulating cell proliferation, differentiation and survival. They exert a wide spectrum of biological activities selectively binding to and activating specific membrane receptors which then transfer the message to cell interior inducing specific biochemical pathways. GFs are especially involved in the regulation of angiogenesis, a physiological process underlining several pathologies. Among the pro-angiogenic growth factors are FGF, PDGF and VEGF. Platelet-derived growth factor (PDGF) also has been shown in vivo to increase bone formation and supplement fracture healing, and may have a role as a therapeutic agent in the treatment of bone loss and fracture healing in humans. Further uses of PDGF receptor agonists are to improve wound healing and its role to stimulate the formation of stem-cell derived neurons for treatment of Parkinson’s disease is under investigation.

While agonists of the PDGF receptor (PDGF-R) so far are only proteins or genes to express the protein, antagonists of PDGF-R mainly are small molecules to inhibit the receptor tyrosine kinase (RTK). Recently, biologics as specific antagonists of PDGF-R or blockers of the PDGF activity have entered clinical evaluation and it remains to be seen whether selective blockade of PDGF-R will be sufficient to achieve clinical benefit alone or in combination with other anti-angiogenetic treatment modalities. Many of the small molecules targeting PDGF-R include inhibition of VEGF such as the marketed drug sunitinib malate, but other successful examples without VEGF inhibition include imatinib mesylate.

The report includes a compilation of current active projects in research and development of molecules targeting PDG or the PDGF receptor. In addition, the report lists company-specific R&D pipelines of PDGF /-R targeting small molecules, antibodies, proteins, medical devices and DNA. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.
  

Index

• PDGF-R Agonists
• Biologics as PDGF /-R Antagonists
• Imatinib Mesylate Pipeline
• Multi-Target PDGF Receptor Antagonists
• Dual PDGF and VEGF Receptor Antagonists
• Sunitinib Malate Pipeline
• Multi-Target PDGF and VEGF Receptor Antagonists
• Corporate PDGF-R Agonist and Antagonist R&D Pipelines
• About La Merie

Corporate PDGF-R Agonist and Antagonist R&D Pipelines

• AB Science
• Abbott
• ACT Biotech
• Advenchen Laboratories
• Amgen
• Attenuon
• Baxter
• Bayer Schering Pharma
• BioMimetic Therapeutics
• Boehringer Ingelheim
• Cardium Therapeutics
• Celldex Therapeutics
• Deciphera Pharmaceuticals
• Dr Reddy’s Laboratories
• DxS
• Eisai
• Eli Lilly
• Exelixis
• Gene Vector Laboratory
• Genentech
• GlaxoSmithKline (GSK)
• Johnson & Johnson (J&J)
• Jubilant Innovation
• Kuros Biosurgery
• Lupin Pharmaceuticals
• MedImmune (AstraZeneca)
• Millennium
• NeuroNova
• NIAMS
• Novartis
• Ophthotech
• Ortho-McNeil Pharmaceuticals
• Osteohealth (Luitpold Pharmaceuticals)
• Pfizer
• Roche
• SuperGen
• Symphony Evolution
• Takeda Pharmaceutical Co.
• Tigris Pharmaceuticals
• USV Ltd.
• ZymoGenetics

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Pages: 55
Release Date: October of 2009
Format: PDF
Product Code: LMCA0031